The quest for the Grail is beset with challenges.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.
High asset prices and a need to release the pandemic’s brake on growth force medtechs to splash the cash.
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.